Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review
Crossref DOI link: https://doi.org/10.1007/s13300-022-01278-0
Published Online: 2022-06-15
Published Print: 2022-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Delgado, Elías
Jódar, Esteban
Mezquita-Raya, Pedro
Moreno-Pérez, Óscar
Funding for this research was provided by:
AstraZeneca
Text and Data Mining valid from 2022-06-15
Version of Record valid from 2022-06-15
Article History
Received: 3 March 2022
Accepted: 13 May 2022
First Online: 15 June 2022